Pancino G, Toubert M E, Osinaga E, Chatelet F, Leroy M, Schlageter M H, Desroys du Roure F, Calvo F, Teillac P, Najean Y
CNRS-URA, Unité 523, DICA, University of Technology, Compiègne, France.
Int J Cancer. 1991 Jan 21;47(2):221-6. doi: 10.1002/ijc.2910470210.
We have previously reported the production of monoclonal antibody (MAb) 1BE12, which recognizes a glycoprotein in breast-cancer cells. In the present work, 1BE12 reactivity was tested by immunohistochemistry in bladder carcinoma (92 cases) and in non-tumoral bladder samples (15 cases). In 71% of bladder tumors, more than 30% of cells were intensely stained by 1BE12. The percentage of reactive cells was higher in cancers invading the muscle than in more superficial tumors (p = 0.039). In non-tumoral bladder, immuno-staining, when present, was usually confined to the superficial layers with a low number of cells stained (less than 30%) in 13/15 cases. Slot blots, performed on urine samples from 43 bladder-cancer patients and 21 healthy controls, were quantified by densitometry scanning. We found higher optical density (OD) values in urine from muscle-invasive-cancer patients than in urine from more superficial tumors and healthy controls, with a significantly different distribution (p = 0.005). The urinary antigen was detected by immunoblotting with 1BE12 as high-molecular-weight species (greater than 150 kDa). The reactive glycoprotein could thus be purified by immunoaffinity and FPLC filtration from the perchloric-acid-soluble fraction of urine from patients with invasive bladder carcinoma. The availability of purified antigen will allow us to quantitate our assay, in order to evaluate its potential use as a prognostic indicator in bladder-cancer patients.
我们之前报道过单克隆抗体（MAb）1BE12的产生，它可识别乳腺癌细胞中的一种糖蛋白。在本研究中，通过免疫组织化学检测了1BE12在92例膀胱癌和15例非肿瘤性膀胱样本中的反应性。在71%的膀胱肿瘤中，超过30%的细胞被1BE12强烈染色。浸润肌肉的癌症中反应性细胞的百分比高于较浅表肿瘤（p = 0.039）。在非肿瘤性膀胱中，免疫染色（若存在）通常局限于表层，15例中有13例染色细胞数量较少（少于30%）。对43例膀胱癌患者和21例健康对照的尿液样本进行了狭缝印迹，并通过密度扫描进行定量分析。我们发现肌肉浸润性癌患者尿液中的光密度（OD）值高于较浅表肿瘤患者尿液和健康对照，分布有显著差异（p = 0.005）。用1BE12免疫印迹检测到尿液中的抗原为高分子量物质（大于150 kDa）。因此，可通过免疫亲和和快速蛋白质液相色谱（FPLC）过滤从浸润性膀胱癌患者尿液的高氯酸可溶部分中纯化反应性糖蛋白。纯化抗原的可得性将使我们能够对检测进行定量，以便评估其作为膀胱癌患者预后指标的潜在用途。
